Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 16/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10122903 | 0.92 | HRH3 (0.43) | HRH3 | |
| SCHEMBL10107170 | 0.90 | HRH3 (0.39) | HRH3 | |
| SCHEMBL7656218 | 0.86 | HRH3 (0.47) | HRH3 | |
| SCHEMBL14307867 | 0.84 | HRH3 (0.43) | HRH3 | |
| SCHEMBL7660195 | 0.79 | HRH3 (0.47) | HRH3 | |
| SCHEMBL7655220 | 0.76 | HRH3 (0.39) | HRH3 | |
| SCHEMBL7664998 | 0.75 | HRH3 (0.50) | HRH3 | |
| SCHEMBL7659427 | 0.74 | HRH3 (0.67) | HRH3 | |
| SCHEMBL7655188 | 0.71 | HRH3 (0.42) | HRH3 | |
| SCHEMBL7659514 | 0.69 | RAPGEF3 (0.46) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1856098-B1 | PYRAZINYL SUBSTITUTED PIPERAZINE-PIPERIDINES WITH CXCR3 ANTAGONIST ACTIVITY | SCHERING CORP (US) | 2012-08-01 | — | — | EP | disclosed |
| EP-1856097-B1 | PYRIDYL AND PHENYL SUBSTITUTED PIPERAZINE-PIPERIDINES WITH CXCR3 ANTAGONIST ACTIVITY | SCHERING CORP (US) | 2012-07-11 | — | — | EP | disclosed |
| US-8207170-B2 | Heterocyclic substituted piperazines with CXCR3 antagonist activity | SCHERING CORPORATION (US) | 2012-06-26 | — | — | US | disclosed |
| US-20120157466-A1 | HETEROCYCLIC COMPOUNDS WITH CXCR3 ANTAGONIST ACTIVITY | MERCK SHARP & DOHME CORP. | 2012-06-21 | — | — | US | disclosed |
| EP-1937666-B1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS WITH CXCR3 ANTAGONIST ACTIVITY | SCHERING CORP (US) | 2012-02-22 | — | — | EP | disclosed |
| US-8017616-B2 | Heterocyclic substituted pyridine compounds with CXCR3 antagonist activity | SCHERING CORPORATION (US) | 2011-09-13 | — | — | US | disclosed |
| EP-1853583-B1 | AMINE-LINKED PYRIDYL AND PHENYL SUBSTITUTED PIPERAZINE-PIPERIDINES WITH CXCR3 ANTAGONIST ACTIVITY | SCHERING CORP (US) | 2011-09-07 | — | — | EP | disclosed |
| EP-1853587-B1 | NOVEL HETEROCYCLIC SUBSTITUTED PYRIDINE OR PHENYL COMPOUNDS WITH CXCR3 ANTAGONIST ACTIVITY | SCHERING CORP (US) | 2011-08-03 | — | — | EP | disclosed |
| US-20110065651-A1 | HETEROCYCLIC SUBSTITUTED PIPERAZINES WITH CXCR3 ANTAGONIST ACTIVITY | SCHERING CORPORATION (US) | 2011-03-17 | — | — | US | disclosed |
| US-7902199-B2 | Chemokine receptor CXCR3; inflammatory conditions (psoriasis and inflammatory bowel disease), autoimmune diseases, graft rejection, infectious diseases, cancers and tumors, type I diabetes, viral meningitis and tuberculoid leprosy; 1-(pyrid-3-yl)-4-(piperidin-4-yl)piperazines or N-oxides thereof | SCHERING CORPORATION (US) | 2011-03-08 | — | — | US | disclosed |
| US-7417045-B2 | Heterocyclic substituted pyridine or phenyl compounds with CXCR3 antagonist activity | SCHERING CORPORATION (US) | 2008-08-26 | — | — | US | disclosed |
| WO-2008079279-A1 | HETEROCYCLIC COMPOUNDS WITH CXCR3 ANTAGONIST ACTIVITY | SCHERING CORPORATION (US) | 2008-07-03 | — | — | WO | disclosed |
| US-20080058343-A1 | HETEROCYCLIC SUBSTITUTED PIPERAZINE COMPOUNDS WITH CXCR3 ANTAGONIST ACTIVITY | SCHERING CORPORATION AND PHARMACOPEIA, INC. | 2008-03-06 | — | — | US | disclosed |
| US-20080039474-A1 | NOVEL HETEROCYCLIC SUBSTITUTED PYRIDINE COMPOUNDS WITH CXCR3 ANTAGONIST ACTIVITY | SCHERING CORPORATION | 2008-02-14 | — | — | US | disclosed |
| WO-2007109238-A1 | HETEROCYCLIC SUBSTITUTED PYRIDINE COMPOUNDS WITH CXCR3 ANTAGONIST ACTIVITY | SCHERING CORPORATION (US) | 2007-09-27 | — | — | WO | disclosed |
| WO-2007047202-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS WITH CXCR3 ANTAGONIST ACTIVITY | SCHERING CORPORATION (US) | 2007-04-26 | — | — | WO | disclosed |
| US-20070082913-A1 | Substituted heterocyclic compounds with CXCR3 antagonist activity | SCHERING CORPORATION | 2007-04-12 | — | — | US | disclosed |
| US-20070054919-A1 | Pyrazinyl substituted piperazine-piperidines with CXCR3 antagonist activity | SCHERING CORPORATION | 2007-03-08 | — | — | US | disclosed |
| US-20070021611-A1 | Pyridyl and phenyl substituted piperazine-piperidines with CXCR3 antagonist activity | SCHERING CORPORATION | 2007-01-25 | — | — | US | disclosed |
| US-6469002-B1 | COMPOUNDS WHICH MODULATE CHEMOKINE RECEPTOR ACTIVITY AND ARE USEFUL IN TREATMENT OF INFLAMMATORY DISEASES | MILLENNIUM PHARMACEUTICALS, INC. | 2002-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070082913-A1 | Substituted heterocyclic compounds with CXCR3 antagonist activity | CXCR3, CXCL10, CXCR1 | HRH3 233/4885 |
| US-20080058343-A1 | HETEROCYCLIC SUBSTITUTED PIPERAZINE COMPOUNDS WITH CXCR3 ANTAGONIST ACTIVITY | CXCR3, CXCR1, ACKR3 | HRH3 336/4885 |
| US-20120157466-A1 | HETEROCYCLIC COMPOUNDS WITH CXCR3 ANTAGONIST ACTIVITY | CXCR3, ACKR3, CXCR1 | HRH3 292/4885 |
| US-20070054919-A1 | Pyrazinyl substituted piperazine-piperidines with CXCR3 antagonist activity | CXCR3, CXCR1, CCR5 | HRH3 260/4885 |
| US-20110065651-A1 | HETEROCYCLIC SUBSTITUTED PIPERAZINES WITH CXCR3 ANTAGONIST ACTIVITY | CXCR3, CXCR1, CCR5 | HRH3 215/4885 |
| US-20070021611-A1 | Pyridyl and phenyl substituted piperazine-piperidines with CXCR3 antagonist activity | CXCR3, CCR1, CCR5 | HRH3 243/4885 |
| US-20080039474-A1 | NOVEL HETEROCYCLIC SUBSTITUTED PYRIDINE COMPOUNDS WITH CXCR3 ANTAGONIST ACTIVITY | CXCR3, CXCR1, ACKR3 | HRH3 186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.